Aligos Therapeutics, Inc. OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax
Aligos Therapeutics, Inc. (ALGS) reported OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax of -$1.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax · last filed 2026-08-06
- Aligos Therapeutics, Inc. oci, debt securities, available-for-sale, gain (loss), after adjustment and tax for the quarter ending 2026-06-30 was -$1.00K.
- Aligos Therapeutics, Inc. oci, debt securities, available-for-sale, gain (loss), after adjustment and tax for the quarter ending 2026-03-31 was -$30.00K.
- Aligos Therapeutics, Inc. oci, debt securities, available-for-sale, gain (loss), after adjustment and tax for the quarter ending 2025-12-31 was $18.00K.
- Aligos Therapeutics, Inc. oci, debt securities, available-for-sale, gain (loss), after adjustment and tax for the quarter ending 2025-09-30 was $35.00K, a 57.83% decline year-over-year.
- Aligos Therapeutics, Inc. oci, debt securities, available-for-sale, gain (loss), after adjustment and tax for fiscal 2025 was $22.00K, a 144.44% increase from fiscal 2024.
- Aligos Therapeutics, Inc. oci, debt securities, available-for-sale, gain (loss), after adjustment and tax for fiscal 2024 was $9.00K, a 90.63% decline from fiscal 2023.
- Aligos Therapeutics, Inc. oci, debt securities, available-for-sale, gain (loss), after adjustment and tax for fiscal 2023 was $96.00K.
- Aligos Therapeutics, Inc. oci, debt securities, available-for-sale, gain (loss), after adjustment and tax for fiscal 2022 was -$57.00K.
| Period end | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax 3 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax 6 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax 9 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.00K 10-Q · filed 2026-08-06 | -$31.00K 10-Q · filed 2026-08-06 | -$13.00K derived: sum of 3 quarters · filed 2026-08-06 | $22.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$30.00K 10-Q · filed 2026-05-07 | -$12.00K derived: sum of 2 quarters · filed 2026-05-07 | $23.00K derived: sum of 3 quarters · filed 2026-05-07 | -$4.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $18.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $53.00K derived: sum of 2 quarters · filed 2026-03-05 | $26.00K derived: sum of 3 quarters · filed 2026-08-06 | $22.00K 10-K · filed 2026-03-05 |
| 2025-09-30 | $35.00K 10-Q · filed 2025-11-06 | $8.00K derived: sum of 2 quarters · filed 2026-08-06 | $4.00K 10-Q · filed 2025-11-06 | -$19.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$27.00K 10-Q · filed 2026-08-06 | -$31.00K 10-Q · filed 2026-08-06 | -$54.00K derived: sum of 3 quarters · filed 2026-08-06 | $29.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$4.00K 10-Q · filed 2026-05-07 | -$27.00K derived: sum of 2 quarters · filed 2026-05-07 | $56.00K derived: sum of 3 quarters · filed 2026-05-07 | $74.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$23.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $60.00K derived: sum of 2 quarters · filed 2026-03-05 | $78.00K derived: sum of 3 quarters · filed 2026-03-05 | $9.00K 10-K · filed 2026-03-05 |
| 2024-09-30 | $83.00K 10-Q · filed 2025-11-06 | $101.00K derived: sum of 2 quarters · filed 2025-11-06 | $32.00K 10-Q · filed 2025-11-06 | $32.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $18.00K 10-Q · filed 2025-08-06 | -$51.00K 10-Q · filed 2025-08-06 | -$51.00K derived: sum of 3 quarters · filed 2025-08-06 | -$51.00K derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | -$69.00K 10-Q · filed 2025-05-06 | -$69.00K derived: sum of 2 quarters · filed 2025-05-06 | -$69.00K derived: sum of 3 quarters · filed 2025-05-06 | -$71.00K derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $0.00 derived: sum of 2 quarters · filed 2025-03-10 | -$2.00K derived: sum of 3 quarters · filed 2025-03-10 | $96.00K 10-K · filed 2025-03-10 |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-02 | -$2.00K derived: sum of 2 quarters · filed 2024-08-06 | $96.00K 10-Q · filed 2024-11-06 | $332.00K derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-06-30 | -$2.00K 10-Q · filed 2024-08-06 | $96.00K 10-Q · filed 2024-08-06 | $332.00K derived: sum of 3 quarters · filed 2024-08-06 | $441.00K derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $98.00K 10-Q · filed 2024-05-07 | $334.00K derived: sum of 2 quarters · filed 2024-05-07 | $443.00K derived: sum of 3 quarters · filed 2024-05-07 | $289.00K derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $236.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $345.00K derived: sum of 2 quarters · filed 2024-03-12 | $191.00K derived: sum of 3 quarters · filed 2024-03-12 | -$57.00K 10-K · filed 2024-03-12 |
| 2022-09-30 | $109.00K 10-Q · filed 2023-11-02 | -$45.00K derived: sum of 2 quarters · filed 2023-11-02 | -$293.00K 10-Q · filed 2023-11-02 | |
| 2022-06-30 | -$154.00K 10-Q · filed 2023-08-03 | -$402.00K 10-Q · filed 2023-08-03 | ||
| 2022-03-31 | -$248.00K 10-Q · filed 2023-05-04 | |||
| 2021-09-30 | -$1.00K 10-Q · filed 2022-11-02 | -$27.00K derived: sum of 2 quarters · filed 2022-11-02 | -$67.00K 10-Q · filed 2022-11-02 | |
| 2021-06-30 | -$26.00K 10-Q · filed 2022-08-04 | -$66.00K 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | -$41.00K 10-Q · filed 2022-05-04 | |||
| 2020-09-30 | -$105.00K 10-Q · filed 2021-11-04 | -$269.00K derived: sum of 2 quarters · filed 2021-11-04 | $132.00K 10-Q · filed 2021-11-04 | |
| 2020-06-30 | -$164.00K 10-Q · filed 2021-08-05 | $238.00K 10-Q · filed 2021-08-05 | ||
| 2020-03-31 | $401.00K 10-Q · filed 2021-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |